$QURE News

uniQure (QURE) Stock Could Be Fully Valued As It Files For AMT 130 Approval

QURE Stock Fades After AMT-130 filing — But William Blair Sees 58% Upside

UniQure's Embattled Huntington's Gene Therapy Clears A Key Hurdle

William Blair Reinstates Outperform on uniQure

uniQure Filed for Huntington's Approval. Acceptance Is the Catalyst, Analyst Says

uniQure Announces Submission of Biologics License Application for Ifezuntirgene Inilparvovec (AMT-130) in Huntington’s Disease

uniQure Submits Biologics License Application to FDA for Accelerated Approval of Ifezuntirgene Inilparvovec (AMT-130), Gene Therapy for Huntington’s Disease

uniQure (QURE) Q2 2026 Earnings Call Transcript

Wells Fargo Maintains Overweight on uniQure, Raises Price Target to $75

Wolfe Research Upgrades uniQure to Outperform, Announces $65 Price Target

Barclays Maintains Overweight on uniQure, Lowers Price Target to $60

uniQure NV (QURE) Q2 2026 Earnings Call Highlights: Strategic Advances Amid Operational Challenges

uniQure Q2 Earnings Call Highlights

AdCom expected for uniQure’s Huntington’s gene therapy, chief medical officer says

uniQure N.V. (QURE) Q2 2026 Earnings Call Transcript

UniQure (NASDAQ:QURE) Rises on Pipeline Progress Despite Wider Q2 Loss

uniQure (QURE) Reports Q2 Loss, Misses Revenue Estimates

uniQure Announces Second Quarter 2026 Financial Results and Provides Company Update

uniQure Q2 EPS $(1.22) Misses $(0.82) Estimate, Sales $5.800M Beat $5.467M Estimate

HC Wainwright & Co. Maintains Buy on uniQure, Raises Price Target to $80